IL142548A0 - Genes for assessing cardiovascular status and compositions for use thereof - Google Patents

Genes for assessing cardiovascular status and compositions for use thereof

Info

Publication number
IL142548A0
IL142548A0 IL14254899A IL14254899A IL142548A0 IL 142548 A0 IL142548 A0 IL 142548A0 IL 14254899 A IL14254899 A IL 14254899A IL 14254899 A IL14254899 A IL 14254899A IL 142548 A0 IL142548 A0 IL 142548A0
Authority
IL
Israel
Prior art keywords
genes
compositions
cardiovascular status
assessing cardiovascular
assessing
Prior art date
Application number
IL14254899A
Original Assignee
Pyrosequencing Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pyrosequencing Ab filed Critical Pyrosequencing Ab
Publication of IL142548A0 publication Critical patent/IL142548A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6486—Renin (3.4.23.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23015—Renin (3.4.23.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
IL14254899A 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof IL142548A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10430298P 1998-10-14 1998-10-14
US10428698P 1998-10-14 1998-10-14
PCT/IB1999/001678 WO2000022166A2 (en) 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof

Publications (1)

Publication Number Publication Date
IL142548A0 true IL142548A0 (en) 2002-03-10

Family

ID=26801367

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14254899A IL142548A0 (en) 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof

Country Status (7)

Country Link
EP (1) EP1121462A2 (en)
JP (1) JP2002527079A (en)
AU (1) AU6116399A (en)
CA (1) CA2347247A1 (en)
IL (1) IL142548A0 (en)
NO (1) NO20011847L (en)
WO (1) WO2000022166A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938390A1 (en) * 1999-08-05 2001-03-08 Max Delbrueck Centrum New sequence variants of the human ßl adrenoceptor gene and their use
WO2002000933A2 (en) * 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US20030113726A1 (en) * 2000-12-04 2003-06-19 Zenta Tsuchihashi Human single nucleotide polymorphisms
DE10065666B4 (en) * 2000-12-29 2008-10-02 Wiesner, Rudolf, Prof. Dr. DNA chip for the causal diagnosis of hypertension
WO2002063045A1 (en) * 2001-02-02 2002-08-15 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the angiotensin receptor 2 gene
EP1394267A1 (en) * 2002-08-19 2004-03-03 Bayer HealthCare AG Single nucleotide polymorphisms predictive for cardiovascular disease, adverse drug reactions, and drug efficacy
JP4502570B2 (en) * 2002-09-24 2010-07-14 株式会社東洋紡ジーンアナリシス IgA nephropathy diagnosis using genetic polymorphism analysis and IgA nephropathy diagnosis kit
WO2006031955A2 (en) 2004-09-14 2006-03-23 The Regents Of The University Of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting
JP2008528054A (en) 2005-02-02 2008-07-31 ロイヤル カレッジ オブ サージョンズ イン アイルランド Pharmacogenomics of antihypertensive agents
AU2006227283B2 (en) * 2005-03-22 2010-07-01 Novartis Ag Biomarkers for efficacy of aliskiren as a hypertensive agent
US7482124B2 (en) * 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
US20110159493A1 (en) 2008-07-03 2011-06-30 Offer Amir Diagnostic polymorphisms for cardiac disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6549186A (en) * 1985-10-24 1987-05-19 Biotechnology Research Partners Limited Blood tests diagnostic for hypertension
WO1988008457A1 (en) * 1987-04-30 1988-11-03 Biotechnology Research Partners, Ltd. Hypertension-related blood tests useful as genetic markers
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US6197505B1 (en) * 1997-04-04 2001-03-06 Pyrosequencing Ab Methods for assessing cardiovascular status and compositions for use thereof
WO1999037761A1 (en) * 1997-12-30 1999-07-29 Max-Delbrück-Centrum für Molekulare Medizin Novel sequence variants of the human beta2-adrenergic receptor gene and use thereof

Also Published As

Publication number Publication date
NO20011847L (en) 2001-06-14
WO2000022166A2 (en) 2000-04-20
EP1121462A2 (en) 2001-08-08
AU6116399A (en) 2000-05-01
NO20011847D0 (en) 2001-04-10
CA2347247A1 (en) 2000-04-20
JP2002527079A (en) 2002-08-27
WO2000022166A3 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
HK1040414A1 (en) Elongase genes and uses thereof
AP2000001874A0 (en) Cellecoxib compositions
HUP0103562A3 (en) Novel compositions and use
GB9813271D0 (en) Composition and use
BG105437A (en) Rheoogy modified compositions and processes thereof
EP1056456A4 (en) R-lansoprazole compositions and methods
IL138178A0 (en) Identifiable marking compositions and methods
IL142548A0 (en) Genes for assessing cardiovascular status and compositions for use thereof
EP1056457A4 (en) S-lansoprazole compositions and methods
IL142635A0 (en) Compositions and methods using lactadherin or variants thereof
PL339175A1 (en) Synergetic compositions containing imazalyl and epoxyconazole
GB9811168D0 (en) Direct hair-colouring compositions and the use thereof
EP1073333A4 (en) S-rabeprazole compositions and methods
GB9725387D0 (en) Oxygen-scavenging compositions
HUP9800596A3 (en) Antifungal compositions and use thereof
GB9922135D0 (en) Compositions and uses
IL145711A0 (en) Thrombospondin-2 and uses thereof
GB2336535B (en) Compositions
IL140190A0 (en) Response assessment
HUP0201048A2 (en) Pseudomycin antifungal compositions and their use
EP1073332A4 (en) R-rabeprazole compositions and methods
GB9921009D0 (en) Essential genes and assays relating thereto
PL338379A1 (en) Novel photoinitiators and their application
GB9803773D0 (en) Compositions and their use
GB9805172D0 (en) Composition and use